Have a question? Give us a call! 800-979-2869
Check out our latest deals!
Pfizer Animal Health
Feline Infectious Peritonitis Vaccine, Modified Live
U.S. Vet. Lic. No.: 189
Description: PRIMUCELL FIP® contains an attenuated,
temperature-sensitive (TS) strain of FIP virus propagated on an
established feline cell line. The vaccine is freeze-dried to preserve
Contains gentamicin as preservative.
Indications: PRIMUCELL FIP® is for intranasal (IN) vaccination of
healthy cats 16 weeks of age or older as an aid in preventing feline
infectious peritonitis caused by feline infectious peritonitis virus
Cats vaccinated IN with PRIMUCELL FIP® develop a protective immune response and do
not become hypersensitized. This practical benefit may be attributed to
the temperature-sensitive PRIMUCELL FIP®
vaccine strain, which replicates in the upper respiratory tract, but
does not spread systemically at 39°C, the cat's body temperature.
1. General Directions: Vaccination of healthy cats is
recommended. Aseptically rehydrate the freeze-dried vaccine with the
sterile diluent provided. Mix well. Use dropper to inoculate entire
volume into nasal passages (1/2 volume into each nasal passage). Cats
may sneeze or shake their heads at the time of administration.
2. Primary Vaccination: Healthy cats 16 weeks of age or
older should receive 2 IN doses administered 3-4 weeks apart.
3. Revaccination: Annual revaccination with a single
dose is recommended.
Precaution(s): Store at 2°-7°C.
Prolonged exposure to higher temperatures and/or direct sunlight may
adversely affect potency. Do not freeze.
Use entire contents when first opened.
Burn containers and all unused contents.
Caution(s): Droppers should be used
to administer this vaccine.
As with many vaccines, anaphylaxis may occur after use.
Initial antidote of epinephrine is recommended and should be followed
with appropriate supportive therapy.
This product has been shown to be efficacious in healthy
animals. A protective immune response may not be elicited if animals
are incubating an infectious disease, are malnourished or parasitized,
are stressed due to shipment or environmental conditions, are otherwise
immunocompromised, or the vaccine is not administered in accordance with
Warning(s): For use in cats only.
For veterinary use only.
Discussion: Disease Description: FIP
is a complex disease of cats caused by FIPV, a coronavirus related to
transmissible gastroenteritis virus (TGEV) of pigs, enteric coronavirus
of dogs, and respiratory coronavirus of humans.1
Although scientists do not completely understand its
pathogenesis, they believe that FIP is an immune-mediated disease. FIPV
first multiplies in epithelial cells of the upper respiratory tract and
intestine.2 Clinically apparent FIP
occurs after the virus crosses the mucosal barrier and spreads
throughout the cat in infected macrophages and monocytes.
Primary FIP may be mild, consisting of fever and a
slight nasal and ocular discharge. While most cats with the primary form
of FIP recover, others become chronically infected carriers. Secondary
FIP may develop following primary infection and appears in 2 forms: (1)
Effusive or wet form, characterized by peritonitis and pleuritis with
ascites and pleural effusion, and (2) Noneffusive or dry form,
characterized by granulomatous inflammation of various organs and little
or no exudate.3,4 Both forms may appear
Once clinical symptoms occur, FIP usually takes a fatal
course. The most commonly diagnosed clinical manifestation is
accumulation of fluid within the peritoneal cavity with progressive,
painless enlargement of the abdomen. Infected animals also may
experience difficult breathing, have an elevated temperature, appear
depressed, and lose weight. Other clinical symptoms, such as ocular
involvement, disseminated intravascular coagulation, and renal
involvement, are observed occasionally.5
Exudate obtained from body cavities by paracentesis appears pale yellow
or golden in color and is relatively clear. Hemograms of cats with FIP
typically indicate a stress response. There may be a mild to moderate
anemia and leukocytosis attributed to an increased percentage of
FIP most frequently occurs in young cats between the
ages of 6 months and 2 years of age. Incidence of disease is also higher
in older cats, between 11 and 15 years of age.
Trial Data: Safety and Efficacy:
Comprehensive tests were conducted to demonstrate the safety of
In these tests, PRIMUCELL FIP®
did not cause illness in cats when administered intranasally. It did
not cause illness in cats infected with feline leukemia, in cats exposed
to feline enteric coronavirus, in dexamethasone-immunosuppressed cats,
in nonvaccinated cats that survived FIP challenge, or in kittens.
PRIMUCELL FIP® did not
interfere with the development of an antibody response to any of the
following feline vaccine antigens: feline leukemia virus, feline
rhinotracheitis virus, feline calicivirus, feline panleukopenia virus,
and Chlamydia psittaci. Conversely, none of
these vaccine antigens interfered with the immunogenicity of PRIMUCELL
Efficacy of PRIMUCELL FIP®
also was demonstrated in a series of tests.
In the first of 2 immunogenicity studies, 20
seronegative cats were vaccinated with a 2-dose primary regimen (given 3
weeks apart). All vaccinates developed FIPV antibody titers, and 17 of
the 20 (85%) survived an FIPV challenge that caused FIP in 12 of 12
(100%) nonvaccinated controls. Ten of the 12 controls died. Sixteen of
the 17 (94%) vaccinated cats that survived the first challenge survived a
second challenge, which caused FIP in 4 of 6 nonvaccinated controls.
In the second immunogenicity study, 20 of 20
seronegative cats developed FIPV antibody titers after primary
vaccination with 2 doses given 3 weeks apart. Fifteen of 20 (75%)
vaccinates were protected against a challenge of immunity in which 7 of
10 (70%) nonvaccinated control cats died of FIP. All but 1 of the
surviving vaccinated cats from the first challenge survived a second
challenge, which killed 6 of 6 nonvaccinated controls.
In addition to protecting against homologous challenge,
PRIMUCELL FIP® also protected cats
against a heterologous challenge strain (WSU-1146). Clinical FIP
symptoms of vaccinated cats were significantly lower (P) than symptoms
of control cats following WSU-1146 challenge. Eight of 10 (80%)
vaccinated cats survived a challenge of immunity with the WSU-1146
strain of FIP in which 3 of 5 (60%) non-vaccinated controls died of FIP.
References: Available upon request.
Presentation: Cartons of 25 1-dose
NAC No.: 36901330